undamentalytics Newsletter
Sign in

Anaptysbio, Inc (ANAB) stock

Add to watchlist

Add holding +

NASDAQ: ANAB Nasdaq Biotechnology Next results ~November 3, 2026

A Fundamentals grade

Anaptysbio, Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$61

Valuation models combined (3)

Base case. Range ~$53–$68. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Anaptysbio, Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 8 selling0 purchases and 42 sales by directors and officers, last 12 monthsInsider trades
  • Funds113 adding, 101 cuttingOf 47 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Anaptysbio files

Where Anaptysbio stands after its latest 10-Q

Revenue for the twelve months to March 2026 was $238m, up 92.9% on a year earlier, slower than the 107.7% growth a quarter earlier. Free-cash-flow margin rose to 1.9% from -97.6% a year earlier. Operating margin widened to 131.7% from 77.1%. The diluted share count is up 7.5% on a year earlier, which dilutes existing holders. It passes 1 of our 1 financial-health checks. Our valuation models combined value is $76.02 a share, against a share price of $50.20.

Source: 10-Q filed May 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Anaptysbio, Inc's trailing-twelve-month revenue grew 92.9% year on year, with a free-cash-flow margin of 1.9%. Where it stands out: operating margin of 131.7% ranks 1 of 175 biotechnology companies we cover.

Current signal Operating margin expanding: TTM operating margin reached 131.7%, up 54.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 92.9% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • High operating margin. 131.7% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 54.6 points on a year ago.
  • Shrinking share count. Diluted shares fell 2.5% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Growth slowing. The growth rate is 14.8 points lower than a quarter earlier.
  • Volatile shares. Over the past year the shares showed annualised volatility of 63% and a beta of 0.9 against the S&P 500.
  • Weak cash conversion. Free cash flow was 2% of net income over the last 12 months.
  • Heavily shorted. 39.7% of the shares available to trade are sold short (9.4 days of average volume to cover).
  • Estimates being cut. Analysts' consensus for next year's earnings per share has fallen 13.3% over 90 days.

Latest results: FY2026 Q2

Filed September 21, 2026
Earnings per share
$4.93 against an average estimate of $0.14: beat by 3384.4%
Revenue
$27m, up 23.5% on a year earlier
Guidance given
annualized Jemperli royalties payable to Anaptys $390m (as early as 2029); paydown of remaining non-recourse debt monetization (Sagard) $325m (by the end of Q2 2027)
Next report
November 3, 2026; average EPS estimate $0.53

Anaptysbio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.8%
  • 1 week-3.8%
  • 1 month-3.3%
  • This year+45.1%
  • 1 year+92.4%
  • 5 years+106.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$238M
Operating margin
131.7%
Net margin
82.4%
EPS (TTM, diluted)
$6.58

Growth

Revenue growth
+92.9%
Change in growth rate
−14.8 pts
Share count change
−2.5%

Cash

Free cash flow (TTM)
$4.4M
FCF margin
1.9%
Stock pay % of revenue
-2.7%

Earnings

Last results
May 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Anaptysbio, Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Anaptysbio, Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.05 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$68 ~$43–$89 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$56 ~$54–$110 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$18 ~$18–$69 Left out: far from the other models (more than 3x away from their median)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$53 ~$44–$63 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$61 ~$53–$68 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Anaptysbio, Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201720182019202020212022202320242025
Share price$67.15$42.53$10.83$14.33$23.17$20.66$14.28$8.83$32.32
Market value$1.3bn$1.0bn$293m$391m$635m$582m$384m$261m$977m
+ Net debt (− = net cash)−$74m−$106m−$170m−$250m−$496m−$71m−$36m−$23m−$138m
Enterprise value$1.3bn$943m$123m$141m$140m$511m$349m$238m$839m
Multiples
Price / sales 132.8xn/m36.6x5.2x10.1x56.6x22.4x2.9x4.2x
Price / earnings —————————
Price / free cash flow ————————49.8x
EV / EBITDA ———————3.6x3.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

13 /100

Weak moat

How hard Anaptysbio's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -17.2% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -449.2%; its worst year was -1547.0%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -185.5% of revenue.

  • Discipline 4 / 20

    The diluted share count rose 8.9% over five years; stock-based pay has been a median 94.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (18 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $33m and EPS of $0.53 (range $0.00 to $1.29) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $4.20 +1013% $101m −57%
Next $4.54 +8% $171m +69%

Next year's EPS estimate has moved −13.3% in 90 days, across 5 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1919.4% on 90 days ago. In the last 30 days, 2 analysts raised Anaptysbio, Inc's forecast and 0 cut it.

Consensus EPS forecast Anaptysbio, Inc, last 90 days
−$2.00 $0.00 $2.00 $4.00 $6.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.23 Current fiscal year, 60 days ago: −$0.47 Current fiscal year, 30 days ago: $4.78 Current fiscal year, 7 days ago: $4.35 Current fiscal year, Now: $4.20 $4.20 Next fiscal year, 90 days ago: $5.24 Next fiscal year, 60 days ago: $4.35 Next fiscal year, 30 days ago: $5.54 Next fiscal year, 7 days ago: $5.07 Next fiscal year, Now: $4.54 $4.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.23$5.24
60 days ago −$0.47$4.35
30 days ago $4.78$5.54
7 days ago $4.35$5.07
Now $4.20$4.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.14 $4.93 +3384.4%
Dec 2025 $0.93 $1.58 +69.3%
Sept 2025 −$1.25 $0.52 +141.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, May 12, 2026
  • annualized Jemperli royalties payable to Anaptys · Jemperli (GSK collaboration) as early as 2029 about $390m
    “Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK's peak sales guidance of >$2.7 billion” source
  • paydown of remaining non-recourse debt monetization (Sagard) · Sagard non-recourse debt monetization by the end of Q2 2027 about $325m
    “Anaptys estimates Sagard will have accrued ~$275 million in royalties and sales milestones through Q1 2026 and anticipates paydown of the remaining ~$325 million non-recourse debt monetization by the end of Q2 2027” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

8 analysts, Oct 2026
Buy8100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026358
  2. Sep 2026358
  3. Aug 20263710
  4. Jul 20263811

Counts of recommendations published by analysts covering Anaptysbio, Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
39.7%
of tradable shares
Days to cover
9.41
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
5.6%
of shares

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +92.4%

$24.39 on October 31, 2025 to $46.91

ThenNowEffect
Revenue (last 12 months) $123m $238m +92.9%
P/S multiple 6.1x 5.9x −3.9%
Share count 31m 30m +3.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +301.4%

$11.69 on November 3, 2023 to $46.91

ThenNowEffect
Revenue (last 12 months) $13m $238m +1737.0%
P/S multiple 25.1x 5.9x −76.6%
Share count 28m 30m −6.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ANAB+62%−11%−31%−38%+266%+45%
Industry peers (median)−36%−57%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ANAB75%50%25%58%75%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ANAB−46%−48%−55%−68%−31%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since January 26, 2017: 92% from March 2, 2018 to November 8, 2019. Getting back needed a 1163% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$22.06 – $69.81
From 52-week high
−32.8%
vs 50-day average
−9.0%
vs 200-day average
−7.1%
Volatility (1 year)
63%
Beta vs S&P 500
0.88

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±6.9%
After a week
5 up, 7 down
typical move ±6.9%
After a month
8 up, 4 down
typical move ±11.6%
Results releasedNext dayS&P 500 next day5 days21 days
May 12, 2026 −7.7% +0.4% −12.0% −20.1%
March 3, 2026 +10.3% −0.2% +12.9% +3.3%
January 9, 2026 +11.9% +0.8% +4.3% +14.7%
November 4, 2025 −0.1% −0.8% −6.9% +20.1%
August 6, 2025 −14.0% +0.7% −12.5% −7.6%
May 5, 2025 −5.1% −1.4% −5.5% +0.4%
February 27, 2025 −1.1% −0.1% −3.5% +11.5%
November 5, 2024 +11.4% +3.7% +7.8% +18.7%
August 5, 2024 −2.1% −2.0% +3.0% +13.3%
May 9, 2024 −9.1% +0.7% −1.1% −8.3%
March 11, 2024 +5.1% +1.0% −6.6% −10.6%
January 5, 2024 +4.3% +1.6% +7.0% +11.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Anaptysbio, Inc in five measures

Fundamentals grade A
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Anaptysbio, Inc
$0 $100M $200M $300M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $15M Revenue (TTM), FY23 Q4: $17.2M Revenue (TTM), FY24 Q1: $23M Revenue (TTM), FY24 Q2: $30.5M Revenue (TTM), FY24 Q3: $57.2M Revenue (TTM), FY24 Q4: $91.3M Revenue (TTM), FY25 Q1: $111.9M Revenue (TTM), FY25 Q2: $123.2M Revenue (TTM), FY25 Q3: $169.5M Revenue (TTM), FY25 Q4: $234.6M Revenue (TTM), FY26 Q1: $232.4M Revenue (TTM), FY26 Q2: $237.6M $237.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $15M
FY23 Q4 $17.2M
FY24 Q1 $23M
FY24 Q2 $30.5M
FY24 Q3 $57.2M
FY24 Q4 $91.3M
FY25 Q1 $111.9M
FY25 Q2 $123.2M
FY25 Q3 $169.5M
FY25 Q4 $234.6M
FY26 Q1 $232.4M
FY26 Q2 $237.6M
Revenue growth, TTM YoY Anaptysbio, Inc
0% 200% 400% 600% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 233.2% Revenue growth, TTM YoY, FY23 Q4: 66.8% Revenue growth, TTM YoY, FY24 Q1: 114.8% Revenue growth, TTM YoY, FY24 Q2: 135.6% Revenue growth, TTM YoY, FY24 Q3: 282.2% Revenue growth, TTM YoY, FY24 Q4: 432.0% Revenue growth, TTM YoY, FY25 Q1: 387.2% Revenue growth, TTM YoY, FY25 Q2: 304.2% Revenue growth, TTM YoY, FY25 Q3: 196.4% Revenue growth, TTM YoY, FY25 Q4: 157.0% Revenue growth, TTM YoY, FY26 Q1: 107.7% Revenue growth, TTM YoY, FY26 Q2: 92.9% 92.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 233.2%
FY23 Q4 66.8%
FY24 Q1 114.8%
FY24 Q2 135.6%
FY24 Q3 282.2%
FY24 Q4 432.0%
FY25 Q1 387.2%
FY25 Q2 304.2%
FY25 Q3 196.4%
FY25 Q4 157.0%
FY26 Q1 107.7%
FY26 Q2 92.9%
Operating margin (TTM) Anaptysbio, Inc
-1000% -500% 0% 500% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -991.0% Operating margin (TTM), FY23 Q4: -958.3% Operating margin (TTM), FY24 Q1: -706.4% Operating margin (TTM), FY24 Q2: -532.9% Operating margin (TTM), FY24 Q3: -257.8% Operating margin (TTM), FY24 Q4: 72.5% Operating margin (TTM), FY25 Q1: 72.2% Operating margin (TTM), FY25 Q2: 77.1% Operating margin (TTM), FY25 Q3: 89.9% Operating margin (TTM), FY25 Q4: 96.7% Operating margin (TTM), FY26 Q1: 94.6% Operating margin (TTM), FY26 Q2: 131.7% 131.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -991.0%
FY23 Q4 -958.3%
FY24 Q1 -706.4%
FY24 Q2 -532.9%
FY24 Q3 -257.8%
FY24 Q4 72.5%
FY25 Q1 72.2%
FY25 Q2 77.1%
FY25 Q3 89.9%
FY25 Q4 96.7%
FY26 Q1 94.6%
FY26 Q2 131.7%
FCF margin (TTM) Anaptysbio, Inc
-800% -600% -400% -200% 0% 200% FY23 Q2 FY24 Q1 FY24 Q4 FY26 Q1 FCF margin (TTM), FY23 Q2: -610.7% FCF margin (TTM), FY23 Q3: -654.0% FCF margin (TTM), FY23 Q4: -708.8% FCF margin (TTM), FY24 Q1: -584.2% FCF margin (TTM), FY24 Q2: -426.3% FCF margin (TTM), FY24 Q3: -180.8% FCF margin (TTM), FY24 Q4: -148.7% FCF margin (TTM), FY25 Q1: -97.6% FCF margin (TTM), FY25 Q2: -104.0% FCF margin (TTM), FY25 Q3: -85.8% FCF margin (TTM), FY25 Q4: 8.4% FCF margin (TTM), FY26 Q1: 1.9% 1.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q2 -610.7%
FY23 Q3 -654.0%
FY23 Q4 -708.8%
FY24 Q1 -584.2%
FY24 Q2 -426.3%
FY24 Q3 -180.8%
FY24 Q4 -148.7%
FY25 Q1 -97.6%
FY25 Q2 -104.0%
FY25 Q3 -85.8%
FY25 Q4 8.4%
FY26 Q1 1.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-KT, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 18 17 10 5 8 75 63 10 17 91 235 238
EBITDA −3 −3 −29 −66 −107 −23 −56 −114 −164 66 227 313
Operating income −3 −3 −29 −67 −107 −24 −57 −115 −164 66 227 313
Net income −5 −4 −30 −62 −97 −20 −58 −129 −164 −145 −13 196
Diluted EPS −$2.12 −$1.62 −$1.52 −$2.50 −$3.60 −$0.73 −$2.11 −$4.57 −$6.08 −$4.92 −$0.44 —
Growth (year on year)
Revenue — −5.0% −40.1% −50.0% +60.0% +837.5% −15.8% −83.7% +66.8% +432.0% +157.0% +92.9%
EBITDA — — — — — — — — — — +242.9% +230.5%
Operating income — — — — — — — — — — +243.0% +229.5%
Margins
EBITDA margin −17.3% −16.7% −286.0% <−999% <−999% −31.1% −89.0% <−999% −954.5% 72.5% 96.7% 131.7%
Operating margin −18.9% −18.1% −287.8% <−999% <−999% −31.8% −89.9% <−999% −958.3% 72.5% 96.7% 131.7%
Net margin −30.8% −25.5% −300.7% <−999% <−999% −26.6% −91.5% <−999% −953.7% −159.1% −5.6% 82.4%
Free-cash-flow margin −56.5% −54.4% −197.3% −991.4% −879.0% −19.6% −74.8% −718.9% −708.8% −148.7% 8.4% —
Cash flow
Cash from operations −10 −9 −19 −49 −70 −14 −46 −74 −121 −135 20 18
Capital spending 0 0 0 1 1 1 1 0 1 0 0 —
Free cash flow −10 −9 −20 −50 −70 −15 −47 −74 −122 −136 20 —
Stock-based pay 1 1 4 — — — 15 27 33 7 4 −6
Free cash flow after stock pay −11 −10 −24 — — — −63 −101 −155 −143 16 —
Balance sheet
Cash 52 51 81 114 171 250 496 71 36 23 138 134
Total debt 0 0 7 8 1 0 0 0 0 0 0 0
Net debt (negative = net cash) −52 −51 −74 −106 −170 −250 −496 −71 −36 −23 −138 −134
Diluted shares 3m 3m 20m 25m 27m 27m 27m 28m 27m 30m 30m —
Returned to shareholders
Buybacks 0 0 0 0 — — 0 0 50 0 69 13
Total returned 0 0 0 0 — — 0 0 50 0 69 13

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 1 checks passed · June 30, 2026
What it owns · $317m
Short-term assets $198mLonger-term assets $119m
What it owes, and who funded it · $46m
Short-term liabilities $35mShareholders' equity $11m
  • Short-term assets cover short-term liabilities $198m of assets due within a year against $35m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Anaptysbio, Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$13.1M
Returned to shareholders
1456%
of free cash flow
Buybacks, last 3 fiscal years
$119M
Diluted share count
−2.5%
year over year
Total shareholder yield
0.9%
dividends 0.0% + buybacks 0.9% of market value
R&D spending
55.4%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ANAB RYTM IDYA PBYI LGND AKBA Median
Revenue, last 12 months $238m $240m $234m $231m $254m $219m $56m
Revenue growth, last 12 months 92.9% 53.5% −70.1% −2.9% 1.0% 7.5% 12.6%
Revenue growth, 3-year average 163.9% 76.3% 94.0% 0.2% 18.2% 2.9% 13.7%
Revenue growth, latest quarter 23.5% 46.9% 55.4% 7.8% −31.8% −21.4% 10.2%
Gross margin — 89.0% — 74.8% 91.9% 79.6% 82.9%
Operating margin 131.7% −83.6% −92.7% 13.2% 10.1% −6.9% −189.4%
Operating margin, 3-year average −108.0% −152.7% −425.5% 13.7% 2.2% −8.9% −363.5%
Net margin 82.4% −85.6% −74.8% 11.6% 20.3% −13.5% −169.8%
Cash from operations / revenue 7.6% −43.9% −47.7% 17.8% 35.9% 19.0% −168.0%
Free-cash-flow margin 1.9% −43.9% −48.6% 17.8% 35.7% 18.4% −162.4%
Free-cash-flow margin, 3-year average −226.6% −79.7% −375.3% 17.2% 32.4% −1.7% −310.0%
Stock pay / revenue −2.7% 36.4% 23.6% 3.1% 22.3% 6.1% 20.0%
Change in share count −2.5% 8.1% 2.1% 3.0% 6.1% 11.8% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 92.9% 12.6% 42 of 172
Change in growth rate Growth -14.8pp -0.1pp 118 of 172
Operating margin Profitability 131.7% -189.4% 1 of 175
Net margin Profitability 82.4% -157.3% 3 of 180
Free-cash-flow margin Cash generation 1.9% -145.4% 41 of 176
Stock pay as % of revenue Cash generation -2.7% 19.2% 2 of 179
Change in share count Balance sheet -2.5% 7.9% 13 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Royalty Management Company $235M 100.0% ▲ 157.0%
Biopharma Company $0 0.0% —

From Anaptysbio, Inc's 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2B
Institutions reporting
210
Shares held vs prior quarter
▲ 6.6%
Positions opened / closed
42 / 36

Top buyers and sellers, Q2 2026: 113 institutions bought and 101 sold ; the biggest buyer was Woodline Partners LP (+373K shares) and the biggest seller Morgan Stanley (−737K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Ecor1 Capital, LLC $532M 7.9M 26.2% 0.0%
Blackrock, Inc. $124M 1.8M 6.1% ▲ 9.7%
Tang Capital Management LLC $89.8M 1.3M 4.4% 0.0%
State Street Corp $86.8M 1.3M 4.3% ▲ 29.6%
Vanguard Capital Management LLC $61.2M 906K 3.0% ▲ 6.2%
Affinity Asset Advisors, LLC $55.8M 826K 2.7% ▼ 12.1%
Sanofi $55.5M 822K 2.7% 0.0%
Millennium Management LLC $54.5M 807K 2.7% ▲ 69.8%
Woodline Partners LP $48.4M 717K 2.4% ▲ 108.3%
683 Capital Management, LLC $44.6M 660K 2.2% ▲ 5.6%
Geode Capital Management, LLC $43.1M 638K 2.1% ▲ 22.6%
Palo Alto Investors LP $40.7M 603K 2.0% ▼ 5.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Anaptysbio, Inc's complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $9.8M 42 trades by 8 insiders · 42% under pre-set plans
Net ▼ $9.8M net selling
Insider Date Trade Shares Price Value
Renton Hollings Director October 1, 2026 Sell pre-set plan 5,000 $49.87 $249,372
Schmid John P. Director March 30, 2026 Sell 522 $57.40 $29,963
Schmid John P. Director March 30, 2026 Sell 7,527 $56.70 $426,781
Schmid John P. Director March 30, 2026 Sell 12,596 $55.71 $701,723
Faga Daniel President, CEO March 27, 2026 Sell 2,570 $57.91 $148,829
Faga Daniel President, CEO March 27, 2026 Sell 510 $56.61 $28,871
Faga Daniel President, CEO March 27, 2026 Sell 3,662 $58.62 $214,666
Faga Daniel President, CEO March 27, 2026 Sell 490 $59.62 $29,214
Faga Daniel President, CEO March 27, 2026 Sell 550 $60.63 $33,346
Faga Daniel President, CEO March 27, 2026 Sell 1,012 $62.15 $62,896
Faga Daniel President, CEO March 27, 2026 Sell 2,592 $63.35 $164,203
Faga Daniel President, CEO March 27, 2026 Sell 3,155 $64.19 $202,519

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around July 31, 2026 estimated from the company's past filing pattern, not announced

  • May 12, 2026
  • March 3, 2026
  • January 9, 2026
  • November 4, 2025
  • August 6, 2025
  • May 5, 2025

Recent SEC filings

Data status

When each part of this page on Anaptysbio, Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Anaptysbio, Inc in brief

What does Anaptysbio, Inc do?
Anaptysbio, Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Anaptysbio, Inc's stock ticker?
Anaptysbio, Inc trades under the ticker ANAB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Anaptysbio, Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Anaptysbio, Inc reported revenue of $238M, 92.9% higher than a year earlier, according to its SEC filings.
What is Anaptysbio, Inc's free cash flow?
Anaptysbio, Inc's free-cash-flow margin is 1.9% of revenue over the trailing twelve months, ranking 41 of the 176 biotechnology companies we cover.
Who are Anaptysbio, Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Ecor1 Capital, LLC, Blackrock, Inc. and Tang Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Anaptysbio, Inc buying back stock, and does it pay a dividend?
Anaptysbio, Inc spent $13.1M on share repurchases over the trailing twelve months, and its diluted share count fell 2.5% over the year.
What is Anaptysbio, Inc's market cap?
On December 31, 2025, Anaptysbio, Inc's market capitalisation was about $977M and net debt of -$138M. Market figures come from third-party market data and may be delayed.
Who are Anaptysbio, Inc's competitors?
In our Biotechnology peer group, the companies closest to Anaptysbio, Inc are Rhythm Pharmaceuticals, Inc., Ideaya Biosciences, Inc., Puma Biotechnology, Inc., Ligand Pharmaceuticals Inc and Akebia Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Anaptysbio, Inc's.
Are insiders buying or selling Anaptysbio, Inc stock?
Over the last 12 months, Anaptysbio, Inc's directors and officers reported 0 open-market purchases and 42 sales on Form 4. The insider trading page charts every trade.
When is Anaptysbio, Inc's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Anaptysbio, Inc announces its own schedule.